Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The New England Journal of Medicine.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045